慢性肾脏病患者使用钆对比剂的风险与选择:综述
该综述探讨了严重慢性肾脏病(CKD)患者使用钆对比剂(GBCA)的风险,包括肾源性系统性纤维化(NSF)的历史教训及当前高稳定性GBCA的应用现状。文章汇总了避免NSF的 restrictive 策略和选择性使用高结合力GBCA的证据,并提及钆脑沉积和可能的系统性综合征等新关切,最后给出严重CKD患者使用GBCA的建议。
要点
- 严重CKD患者使用高结合力GBCA后NSF病例几乎消失,当代研究未观察到NSF。
- 对钆脑沉积及可能的系统性综合征的担忧仍影响严重CKD患者的GBCA使用决策。
- 存在无需GBCA的替代影像学模态可用于严重CKD人群。
核心结论
- 在严重CKD患者中,使用对游离钆具有高结合亲和力的GBCA当代研究显示NSF缺失,但医生仍对GBCA使用存有顾虑。
研究设计与样本
- 本文为综述, critically 回顾严重CKD患者中GBCA使用的文献并提供建议。
主要发现
- 限制性GBCA使用政策及选择性使用结合游离钆更强的GBCA使NSF病例几乎消除。
- 当代严重CKD患者使用高结合亲和力GBCA的研究显示无NSF发生。
- 近期观察发现钆在脑内沉积及可能的GBCA相关系统性综合征,加剧了对严重CKD患者使用GBCA的担忧。
- 放射学进步产生了多种无需GBCA的影像模态,可用于严重CKD人群。
临床怎么用
- 临床医生应权衡严重CKD患者使用GBCA的获益与风险,优先考虑高结合亲和力GBCA及无需GBCA的替代影像模态。
局限性
- 当代研究的局限性被提及,但原文未具体说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gadolinium-based contrast agents (GBCAs) improve the diagnostic capabilities of magnetic resonance imaging. Although initially believed to be without major adverse effects, GBCA use in patients with severe chronic kidney disease (CKD) was demonstrated to cause nephrogenic systemic fibrosis (NSF). Restrictive policies of GBCA use in CKD and selective use of GBCAs that bind free gadolinium more strongly have resulted in the virtual elimination of NSF cases. Contemporary studies of the use of GBCAs with high binding affinity for free gadolinium in severe CKD demonstrate an absence of NSF. Despite these observations and the limitations of contemporary studies, physicians remain concerned about GBCA use in severe CKD. Concerns of GBCA use in severe CKD are magnified by recent observations demonstrating gadolinium deposition in brain and a possible systemic syndrome attributed to GBCAs. Radiologic advances have resulted in several new imaging modalities that can be used in the severe CKD population and that do not require GBCA administration. In this article, we critically review GBCA use in patients with severe CKD and provide recommendations regarding GBCA use in this population.
引用
- Rudnick MR, Wahba IM, Leonberg-Yoo AK, et al. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review. Am J Kidney Dis. 2020. PMID: 32861792. doi:10.1053/j.ajkd.2020.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。